Every cancer, regardless of where it starts in the body, shares a core set of biological traits. Whether it’s a brain tumor, leukemia, or skin cancer, the disease always begins with DNA damage that causes cells to grow without limits, ignore signals telling them to stop, and resist the body’s normal mechanisms for eliminating damaged cells. These shared features are what separate cancer from every other disease.
All Cancers Start With DNA Damage
No single genetic change is enough to cause cancer. Scientists believe that multiple DNA mutations must accumulate in the same cell before it becomes cancerous. Some of these mutations increase the activity of proteins that tell cells to keep dividing. Others disable the proteins responsible for telling cells when to stop growing. Still others knock out the signals that instruct damaged cells to self-destruct. It’s the combination of these changes, not any single one, that transforms a healthy cell into a cancerous one.
These mutations can be inherited, caused by environmental exposures like UV radiation or tobacco smoke, or simply arise from random errors during normal cell division. The specific genes involved vary widely between cancer types, but the pattern is always the same: genes that promote growth get switched on, and genes that restrain growth get switched off.
Uncontrolled Cell Division
Healthy cells go through a tightly regulated cycle of growth, division, and rest. Built-in checkpoints act like quality control stations, pausing the process if something is wrong. Cancer cells bypass these checkpoints. Mutations in checkpoint proteins are found in all types of cancer, because defects in cell cycle control lead to the genetic instability that fuels tumor growth.
One of the defining characteristics of cancer cells is independence from external growth signals. Normal cells wait for chemical instructions from their neighbors before dividing. Cancer cells generate their own growth signals, or they alter their receptors so they fire continuously without any outside input. Once this independence is established, the cell re-enters the division cycle regardless of what the body is telling it to do.
A key target in this process is a protein called Rb, which acts as a master brake on cell division. When Rb is functioning normally, it keeps cells from dividing until conditions are right. In many cancers, Rb is deleted, mutated, or functionally disabled, effectively removing the brake. Viruses like HPV can also knock Rb out of commission, which is why certain infections raise cancer risk.
Resistance to Cell Death
The body has a built-in safety net called apoptosis, a form of programmed cell death designed to eliminate damaged or abnormal cells before they cause harm. Every cancer must find a way around this system to survive. Cancer cells adopt several strategies: they amplify the proteins that block cell death, suppress the proteins that trigger it, or do both at the same time.
These changes happen at every level of cellular machinery. Cancer cells can increase the number of copies of anti-death genes, silence pro-death genes through chemical modifications to their DNA, or alter the proteins themselves after they’re made. The tumor suppressor gene p53, often called the “guardian of the genome,” is mutated or inactivated in roughly half of all human cancers. When p53 goes down, it takes several downstream death-triggering pathways with it.
Cellular Immortality
Normal human cells can only divide a limited number of times. Each division shortens the protective caps on the ends of chromosomes, called telomeres. Once telomeres get too short, the cell stops dividing and eventually dies. This built-in countdown acts as a natural limit on how many times a cell can copy itself.
Cancer cells override this limit by reactivating an enzyme called telomerase, which rebuilds telomeres after each division. This gives cancer cells what researchers call “replicative immortality,” the ability to divide indefinitely. Telomerase reactivation is considered a hallmark of cancer because without it, tumors could never grow large enough to cause harm.
Altered Energy Production
Cancer cells rewire their metabolism in a distinctive way. Normal cells produce most of their energy by processing glucose with oxygen in their mitochondria, a highly efficient method. Cancer cells instead rely heavily on a faster but less efficient process called aerobic glycolysis, burning through glucose even when plenty of oxygen is available. This shift, first observed nearly a century ago, is known as the Warburg effect.
The reason isn’t simply about energy. Rapidly dividing cells need raw materials to build new cells: amino acids, fats, and nucleic acids for DNA. By diverting glucose away from energy production and into these biosynthetic pathways, cancer cells maximize their ability to manufacture the building blocks of new cells. As a side effect, this process produces acid, which gives cancer cells a competitive advantage by creating a hostile environment for normal surrounding tissue. This metabolic shift is so consistent across cancer types that it forms the basis of PET scans, which detect tumors by identifying areas of abnormally high glucose consumption.
Immune System Evasion
Your immune system routinely identifies and destroys abnormal cells. For a cancer to grow, it must find ways to hide from or suppress this surveillance. Tumors accomplish this through several tactics: they restrict the markers on their surface that immune cells use to recognize threats, they actively suppress immune cell activity, and they exhaust the immune cells (particularly T cells) that are trying to attack them.
Tumors also reshape their local environment to favor their own survival. They accumulate specific metabolites and signaling molecules that suppress immune function while simultaneously starving nearby immune cells of the nutrients they need to work. This immune evasion is now recognized as a core feature of all cancers, which is why immunotherapy, treatments designed to re-engage the immune system, has become one of the most important advances in cancer treatment.
Building a Blood Supply
Solid tumors cannot grow beyond a tiny size without recruiting their own blood vessels, a process called angiogenesis. Cancer cells send out chemical signals, most importantly a protein called VEGF, that stimulate nearby blood vessels to sprout new branches toward the tumor. This dedicated blood supply delivers oxygen and nutrients while carrying away waste products.
Tumors don’t rely on just one signal. They release a cocktail of growth factors, adhesion molecules, and enzymes that together drive new vessel formation. The blood vessels that tumors build are typically abnormal: leaky, disorganized, and poorly formed. But they’re functional enough to sustain tumor growth and, critically, to provide a route for cancer cells to enter the bloodstream and spread to distant organs.
Invasion and Metastasis
The single feature that definitively separates cancer from a benign tumor is the ability to invade surrounding tissues and spread to other parts of the body. Benign tumors can grow large and cause problems through pressure or compression, but they stay contained. Cancer cells break through tissue boundaries, enter blood vessels or lymphatic channels, travel to distant organs, and establish new tumors there.
This capacity for invasion and metastasis is what makes cancer dangerous. A tumor that stayed in one place and never spread would be far easier to manage. But the genetic changes that drive uncontrolled growth also tend to activate the cellular machinery for movement and tissue invasion, making metastasis an inherent risk of malignancy rather than an unlucky complication.
Genome Instability Drives It All
Underlying every trait described above is a deeper feature: genomic instability. Normal cells have robust DNA repair systems that catch and fix errors during cell division. In cancer cells, these repair systems are often broken, leading to an accelerating rate of new mutations with each generation of cells. This instability acts as an engine, constantly generating genetic diversity within the tumor.
That diversity is what makes cancer so adaptable. Some cells within a tumor may be resistant to a particular drug, others may be better at evading the immune system, and still others may be primed to metastasize. Chronic inflammation in and around the tumor further fuels this process by creating an environment rich in growth signals and DNA-damaging molecules. Together, genomic instability and tumor-promoting inflammation are considered the two enabling conditions that make all the other hallmarks of cancer possible.